EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer
Werte in diesem Artikel
|
EQS-Ad-hoc: PharmaSGP Holding SE / Key word(s): Personnel PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January 1, 2025. This was decided by the Supervisory Board today. Peter Gerckens succeeds Natalie Weigand in this position. She informed the Supervisory Board today that she has decided not to extend her contract, which expires at the end of the year. However, Natalie Weigand will remain associated with the company in an advisory role after her departure. * * * Contact PharmaSGP Holding SE End of Inside Information
05-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | PharmaSGP Holding SE |
| Lochhamer Schlag 1 | |
| 82166 Gräfelfing | |
| Germany | |
| E-mail: | ir@pharmasgp.com |
| Internet: | https://pharmasgp.com |
| ISIN: | DE000A2P4LJ5 |
| WKN: | A2P4LJ |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Tradegate Exchange |
| EQS News ID: | 2022283 |
| End of Announcement | EQS News Service |
|
|
2022283 05-Nov-2024 CET/CEST
Ausgewählte Hebelprodukte auf PharmaSGP
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf PharmaSGP
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu PharmaSGP
Analysen zu PharmaSGP
Keine Analysen gefunden.